NORDICCTX-III
Live / Applied — Non-final action mailed (as of 03 Feb 2026)
What this means for you
Not registered yet, but its 14 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79433974
- Mark type
- Stylized text
- Filed
- 14 Aug 2025
Goods and services
- Class 005 — Pharmaceuticals: Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations for medical purposes, diagnostic substances and diagnostic materials; medical diagnostic test strips; diagnostic preparations for medical purposes.
- Class 042 — Scientific and technological services: Design and development of the following goods: blood-based biomarkers for the identification, quantification and analysis of disease activity; design and development of the following goods: diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of the following goods: biochemical and pharmaceutical assays and medical samples; design and development of the following goods: biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research relating to the following fields: biomarkers and the detection of biomarkers; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to the following fields: clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data in connection with the following fields: biomarkers; development of the following goods: diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; clinical testing services; diagnostic testing services; testing services relating to the following fields: tracking and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; information, advice and assistance relating to the aforementioned services.
Owner
Prosecution history
- 19 Feb 2026 — REFUSAL PROCESSED BY IB
- 03 Feb 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 03 Feb 2026 — REFUSAL PROCESSED BY MPU
- 08 Jan 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 07 Jan 2026 — NON-FINAL ACTION WRITTEN
- 29 Dec 2025 — ASSIGNED TO EXAMINER
- 05 Oct 2025 — APPLICATION FILING RECEIPT MAILED
- 05 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 02 Oct 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB